Troubled Sucampo Pharmaceuticals Inc. is placing a $200m wager on the potential of bringing the first drug therapy for the rare disorder Niemann-Pick Disease Type C1 (NPC-1) to market, announcing a cash-and-stock buyout of privately held Vtesse Inc. and its pivotal-stage VTS-270 on April 3.
Sucampo has been struggling since it decided to shelve its lead pipeline candidate, cobiprostone, last July following clinical disappointments in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?